Dashboard
Manage Tickers

CNTACentessa Pharmaceuticals plc

Nasdaq centessa.com


$ 9.62 $ 0.07 (0.74 %)    

Thursday, 02-May-2024 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 9.55
$ 9.48
$ 0.00 x 0
$ 0.00 x 0
$ 9.16 - $ 9.62
$ 3.96 - $ 12.45
299,775
na
918.5M
$ 0.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-centessa-pharmaceuticals-prices-100m-public-offering-of-10810810-american-depositary-shares-at-925ads
Reported Earlier, Centessa Pharmaceuticals...
04/24/2024 06:18:39

announces-100m-proposed-public-offering-of-american-depositary-shares
Announces $100M Proposed Public Offering O...
04/23/2024 20:18:36

the-fda-has-cleared-centessa-pharmaceuticals-investigational-new-drug-application-to-initiate-a-phase-1-first-in-human-clinical-trial-of-orx750-for-narcolepsy
The FDA Has Cleared Centessa Pharmaceutica...
04/22/2024 11:09:07

bmo-capital-maintains-outperform-on-centessa-pharmaceuticals-maintains-15-price-target
BMO Capital Maintains Outperform on Centes...
04/01/2024 16:25:57

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 pr...

centessa-pharmaceuticals-q4-eps-038-beats-048-estimate
Centessa Pharmaceuticals Q4 EPS $(0.38) Be...
03/28/2024 20:56:31

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate...

why-take-two-interactive-software-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Take-Two Interactive Software Shares A...
02/09/2024 18:18:14

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter res...

sps-commerce-posts-upbeat-results-joins-masonite-international-impinj-and-other-big-stocks-moving-higher-on-friday
SPS Commerce Posts Upbeat Results, Joins M...
02/09/2024 15:31:44

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ...

centessa-pharmaceuticals-to-present-additional-52-weeks-continuous-treatment-data-from-third-year-ongoing-phase-2a-study-of-serpinpc-for-treatment-of-hemophilia-at-17th-annual-congress-of-european-association-for-haemophilia-and-allied-disorders
Centessa Pharmaceuticals To Present Additi...
02/09/2024 12:09:18

centessa-pharmaceuticals-announced-new-data-from-additional-52-weeks-of-continuous-treatment-from-third-year-part-5-of-ongoing-phase-2a-study-of-serpinpc-for-treatment-of-hemophilia-at-2023-ash-meeting
Centessa Pharmaceuticals Announced New Dat...
12/10/2023 17:57:16

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from t...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/27/2023 21:31:02

Core News & Articles
Anaptys Expands Immune Cell Modulator Pipe...
11/27/2023 21:16:34

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfol...

jefferies-upgrades-centessa-pharmaceuticals-to-buy-raises-price-target-to-11
Jefferies Upgrades Centessa Pharmaceutical...
11/15/2023 11:23:13

Jefferies analyst Kelly Shi upgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Hold to Buy and raises the price target fro...

centessa-pharmaceuticals-q3-eps-040-beats-052-estimate
Centessa Pharmaceuticals Q3 EPS $(0.40) Be...
11/13/2023 22:35:55

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate...

centessa-pharmaceuticals-had-cash-cash-equivalents-and-short-term-investments-of-2813m-as-of-sept-30
Centessa Pharmaceuticals Had Cash, Cash Eq...
11/13/2023 22:15:24

centessa-pharmaceuticals-to-present-additional-52-weeks-of-continuous-treatment-data-from-third-year-of-ongoing-phase-2a-study-of-serpinpc-for-the-treatment-of-hemophilia-at-ash-annual-meeting
Centessa Pharmaceuticals To Present Additi...
11/02/2023 13:12:19

centessa-pharmaceuticals-announces-dosing-of-first-subject-in-registrational-present-3-study-evaluating-serpinpc-for-the-treatment-of-hemophilia-b-with-inhibitors
Centessa Pharmaceuticals Announces Dosing ...
10/31/2023 12:06:24

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medic...

ibm-servicenow-lennox-morningstar-and-other-big-stocks-moving-higher-on-thursday
IBM, ServiceNow, Lennox, Morningstar And O...
10/26/2023 15:55:18

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking t...

morgan-stanley-upgrades-centessa-pharmaceuticals-to-equal-weight-raises-price-target-to-8
Morgan Stanley Upgrades Centessa Pharmaceu...
10/26/2023 09:07:11

Morgan Stanley analyst Matthew Harrison upgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Underweight to Equal-Weight and...

centessa-pharmaceuticals-announces-preclinical-data-from-in-vivo-and-in-witro-studies-of-orx750
Centessa Pharmaceuticals Announces Preclin...
10/25/2023 12:12:52

- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcol...

the-world-sleep-congress-2023-released-an-abstract-submitted-by-centessa-pharmaceuticals-containing-preclinical-data-on-orx750-for-narcolepsy-other-sleep-disorders-data-shows-orx750-promotes-wakefulness-reduces-cataplexy-in-the-orexinataxin-3-mouse
The World Sleep Congress 2023 Released An ...
08/24/2023 10:25:46

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION